A new startup sets course against a constellation of rare diseases with a first shot repurposing the SIRP pathway
Despite some big advances in recent years, rare disease remains a mostly uncharted wilderness with many patients left underserved. A startup with galactic ambitions now hopes to bust open a wide range of such diseases, and its first effort has eyes on a familiar cancer target.
Star Therapeutics emerged from stealth Wednesday focused on cracking the code in a constellation of rare diseases with a first spinout company targeting the SIRP pathway for immunology and cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.